Smith is the founder, CEO and president of New York-based OyaGen Inc., a biotechnology company focused on discovering, developing and commercializing novel pharmaceutical therapies.
Founded in 2015, Germinator’s vision is to provide a safe, effective and non-toxic method of proper sanitizing and disinfecting for businesses and households. The company launched national franchising earlier this year and continues to expand across the U.S., opening 21 new locations across 13 states since February.
Upholding the highest standards of sanitization and disinfection, Germinator makes claims that are scientifically supported and within the Environmental Protection Agency (EPA) regulations. Germinator’s SAB validates the company’s research and process and is responsible for reviewing and advising on product strategy and direction and assisting with navigating legislative and regulatory issues.
In addition to his work with OyaGen, Smith is a full professor at the University of Rochester’s School of Medicine and Dentistry, where he teaches biochemistry and biophysics. He also serves as a senior associate at the University of Rochester Medical Center (URMC) in the Department of Biochemistry and Biophysics. He is a member of URMC’s Center for AIDS Research with a secondary appointment as a professor in the Department of Pathology and Laboratory Medicine. Over his 34 years on the faculty, he has also served as a member of the Cancer Center and Center for RNA Biology.
Smith is an editorial board member of the Journal of Biological Chemistry. He has authored more than 144 peer-reviewed, scientific papers and book chapters and currently holds the rights to several patent applications and issued patents.
In addition to Smith, the SAB includes experts in infectious disease, biological containment and regulatory affairs. The board is made up of key leaders including Dr. Roscoe M. Moore, Jr, who was an assistant to the U.S. Surgeon General for five administrations; Dr. David Miller, the protocol chair of University of Rochester Center for AIDS Research Community Advisory Board; and Chad S. Johnson, Esq., a Harvard-trained corporate, legislative and regulatory attorney with significant experience in advising health and biotechnology companies.